Form SCHEDULE 13G Dave Inc./DE Filed by: FMR LLC
Filed on: November 5, 20
Related stories
Clover Health Reports Q3 Revenue Growth and Raises 2026 Guidance
Clover Health reported Q3 2026 revenue of $759.3 million, up 53% year over year, and GAAP net income of $6.44 million. The company also announced a 5-star rating for its flagship P
M impact | EQUITY | Nov 09, 2026, 07:05 PM UTC
Ondas Issues Q3 2026 Revenue Guidance of $140M-$155M
Ondas projected third-quarter 2026 revenue of $140 million to $155 million, following second-quarter revenue of $83.8 million.
M impact | EQUITY | Nov 09, 2026, 07:04 PM UTC
Con Edison Reports Q3 Adjusted EPS of $2.07, Narrows 2026 Guidance
Con Edison reported third-quarter 2026 adjusted EPS of $2.07, up from $1.90 a year earlier, and revenue of $4.913 billion, up 8.5%. It narrowed full-year 2026 EPS guidance to $6.05
M impact | EQUITY | Nov 09, 2026, 07:03 PM UTC
Nvidia Shares Slide After Board Opens Probe Into Reports
Nvidia's board launched an investigation into reports that CEO Jensen Huang was targeted for spying after a relationship with an executive suspected of working for Chinese intellig
M impact | EQUITY | Nov 09, 2026, 07:02 PM UTC
Analysts Raise Moderna Price Targets After Q3 Results
Goldman Sachs raised its target to $195 from $137, Piper Sandler to $305 from $230, RBC to $145 from $130 and Jefferies to $230 from $200.
M impact | EQUITY | Nov 09, 2026, 07:02 PM UTC
Ma’aden Reports Q3 Revenue Growth, Lower EBITDA and Capex Guidance Cut
Ma’aden said Q3 revenue rose 11% year over year to $3.0 billion, while EBITDA fell 24% to $870 million. The company also cut full-year capital expenditure guidance by approximately
M impact | EQUITY | Nov 09, 2026, 07:02 PM UTC